Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas

Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeitany, Maya, Prabhu, Aishvaryaa, Dakle, Pushkar, Pathak, Elina, Madan, Vikas, Kanojia, Deepika, Mukundan, Vineeth, Jiang, Yan Yi, Landesman, Yosef, Tam, Wai Leong, Kappei, Dennis, Koeffler, H. Phillip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904719/
https://www.ncbi.nlm.nih.gov/pubmed/32851475
http://dx.doi.org/10.1007/s00018-020-03620-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904719/
https://www.ncbi.nlm.nih.gov/pubmed/32851475
http://dx.doi.org/10.1007/s00018-020-03620-w

Ejemplares similares